P53抗体联合CYFRA21-1和CEA在非小细胞肺癌中的应用

目的：研究血清P53抗体在非小细胞肺癌临床病理特征之间的关系,并结合血清中的癌胚抗原、角质蛋白21-1以指导对临床上肺癌复发和转移的分析,用来选择合理的治疗方案。方法：正常组30例,肺良性疾病组10例,肺癌组45例,肺癌全组分别于手术前1天、术后10、30、60和90天时抽取清晨空腹静脉血2ml,23例肺癌病例于手术后120天,15例病例于手术后180天抽取清晨空腹静脉血2ml,肺良性疾病组分别于手术前1天、抽取清晨空腹静脉血2ml。正常组清晨空腹采集静脉血2ml。采用酶联免疫吸附法（ELISA）检测血清P53抗体和角质蛋白21-1,采用荧光酶标免疫法检测血清癌胚抗原。结果：血清P53抗体、CYFRA21-1和CEA在正常人组、良性疾病组、肺癌组术前阳性率的比较三种肿瘤标志物阳性率经X2检验,在肺癌组分别与正常人组和良性病例组有显著性差异（P〈0.05）,良性病例组和正常人组之间无显著行差异（P〉0.05）。并与手术后复发与转移相关。结论：联合检测癌胚抗原、角质蛋白21-1及血清P53抗体水平有助于肺部良恶性疾病的诊断;手术前后动态测定肺癌患者血清P53抗体和角质蛋白21-1的变化规律,有助于判断疗效,监测预后和指导肺癌术后的综合治疗。

P53 Antibody Combined with CYFRA21-1 and CEA in Non-small Cell Lung Cancer

Objective： To evaluate the value of detection sequential changing regularity of serum p53 antibodies combined with CEA and CYFRA21-1 after surgical resection and the relationship between serum p53 antibodies and clinicopathological characteristics in patients with non-small-cell lung cancer.Methods： The serum p53 antibody,CEA and CYFRA21-1 levels were detected in 45 patients with lung cancer in 10 patients with benign pulmonary lesion and 30 healthy adults as control by enzyme linked immunosorbent assay（ELISA）..only these patients who were confirmed to III stage lung cancer by pathology were included in our study.The blood samples in lung cancer group were collected on the day before operation and on the 7th,30th and 90th days postoperatively.23 samples were col-lected on the 120th days postoperatively.Results： The level and positive rate of serum p53 antibodies in patients with lung cancer were significantly higher than those in patients with benign pulmonary disease and normal individuals（P0.05）,but there normal individuals（P0.05）.The level and positive rate of pre-operative serum p53 antibodies in patients with lung cancer were closely related to histopathologic type.The level of serum p53 antibodies decreased gradually in patients with lung cancer underwent radical removal of the cancer,and completely returned to the normal level around the 30th day after operation,but the level of serum p53 antibodies in patients with lung cancer underwent palliative operation didn＇t reduce to the normal level on the 30th day after operation.It would increase again when tumor metastasis or recurrence developed.Conclusion： The results of the study indicate that serum Ab-anti-P53 are relatively often present in advanced NSCLC patients.Serum p53Ab,CEA and CYFRA21-1 can be used at least in association with established tumor markers.